Home / Features / Tesla Motors (NASDAQ:TSLA) Is buying $65M of bonds from SolarCity Corp (SCTY) In Latest Debt Offering

Tesla Motors (NASDAQ:TSLA) Is buying $65M of bonds from SolarCity Corp (SCTY) In Latest Debt Offering

Tesla Motors, Inc. (NASDAQ:TSLA) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 0.86% to close at $224.84 with the total traded volume of 4.75 Million shares. Tesla Motors (TSLA) Chief Executive Elon Musk is buying $65 million of bonds from SolarCity Corp (SCTY) in the latest debt offering by the solar panel company that Tesla plans to acquire for $2.6 billion, according to a filing on Tuesday.

Musk’s purchase of the so-called “solar bonds” comes after money-losing SolarCity last week revealed it would cut operating costs to bring expenses in line with its reduced solar installation outlook. SolarCity Chief Executive Lyndon Rive and Chief Technology Officer Peter Rive are each buying another $17.5 million of the $124 million offer, according to the SolarCity filing. The firm has institutional ownership of 68.30%, while insider ownership included 0.10%. Its price to sales ratio ended at 7.27. TSLA attains analyst recommendation of 2.90 with week performance of 0.55%.

Albany Molecular Research Inc. (NASDAQ:AMRI) [Trend Analysis] surged reacts as active mover, shares an advance 0.20% to traded at $14.77 and the percentage gap between open changing to regular change was 0.61%. AMRI (NASDAQ: AMRI) entered into a non-exclusive commercial license contract with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology and has completed several projects for its consumers. The firm will continue to use the technology to enhance its drug discovery service offerings and internal research and development. Financial terms were not revealed.

“While many people know CRISPR for its potential to edit defective genes to cure disease, there are a range of other applications in drug discovery for which CRISPR has important utility that are critical to our consumers’ R&D projects, notably drug target assessment and in vitro model development for lead discovery and optimization,” stated Christopher Conway, Senior Vice President, Discovery and Development Services at AMRI. The firm’s current ratio calculated as 2.50 for the most recent quarter. The firm past twelve months price to sales ratio was 1.39 and price to cash ratio remained 20.75. As far as the returns are concern, the return on equity was recorded as -12.00% and return on investment was 2.20% while its return on asset stayed at -4.10%. The firm has total debt to equity ratio measured as 1.46.

Credit Suisse Group AG (NYSE:CS) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 1.74% to $12.26. The share price of CS attracts active investors, as stock price of week volatility recorded 1.14%. The stock is going forward to its 52-week low with 22.48% and lagging behind from its 52-week high price with -51.91%.


About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Check Also


Netflix, Inc. (NASDAQ:NFLX) To Admit Defeat In Its Ambition To Conquer The Chinese Market- JAKKS Pacific (NASDAQ:JAKK)

Netflix, Inc. (NASDAQ:NFLX) [Trend Analysis] retains strong position in active trade, as shares scoring -0.43% to …

Leave a Reply

Your email address will not be published. Required fields are marked *